Connect with us

Health

Quebec sees jump in coronavirus infections with 216 new cases

Published

 on

Quebec is continuing to see an increase in its daily number of new novel coronavirus cases after the province reported 216 cases Monday.

The infection figures have continued to climb over the past two weeks and Labour Day marks the second consecutive day the province surpassed the 200 mark.

Health authorities say the latest jump in new cases brings the total to 63,713 since the COVID-19 health crisis began. There have been more than 55,800 recoveries in the province.

Last week, Premier François Legault expressed concerns about the uptick and called on Quebecers to be cautious over the long weekend.

 

One additional death was also recorded Monday and officials say the person died between Aug. 31 and Sept. 5. The death toll stands at 5,770.

Hospitalizations climbed by three to 105. Of them, 18 patients remain in intensive care — the same as the previous day.

Quebec administered 12,737 coronavirus tests on Friday, the latest day for which that information is available. To date, there have been 1,771,867 tests.

Health Minister Christian Dubé is expected to provide an update regarding the situation on Tuesday.

Upward trend in Canada

Quebec, which has been hardest hit by the health crisis, isn’t the only province seeing an increase in cases.

Dr. Theresa Tam, the country’s chief public health doctor, said in a statement Monday that the steady boost in new infections in Canada is a cause for concern.

She says the average daily number of people testing positive over the last week is 545. That is a 25 per cent increase over the previous week which saw a daily average of 435, and 390 a week before that.

“As we enter the fall, Canadians will need to be even more vigilant about following public health guidance, particularly as the cold weather shifts activities indoors,” she said in a statement.

Source: – Global News

Source link

Continue Reading

Health

Race for a COVID-19 vaccine raises cost, safety – and trust – issues – NOW Toronto

Published

 on



In all likelihood, there will be multiple manufacturers distributing their own variations of a vaccine in different countries, but who will have access and at what price?


As COVID-19 numbers rise again, the Prime Minister has re-emerged as a regular fixture at daily government briefings.

On Friday, September 25, Justin Trudeau announced that the federal government has signed another agreement to buy a vaccine. This time with AstraZeneca for up to 20 million doses of its COVID–19 vaccine.

That brings the number of agreements signed by the government with vaccine manufacturers to seven. The others are with Sanofi, GlaxoSmithKline, Johnson & Johnson, Novavax, Pfizer and Moderna.

Three of the companies have vaccine candidates in phase three trials. In all, the government has committed to purchasing some 300 million doses from vaccine manufacturers.

The Trudeau government has also announced its participation in the COVID-19 Vaccine Global Access Facility, or COVAX. It’s part of the World Health Organization’s (WHO) effort to deliver “fair, equitable and timely access to COVID-19 vaccines.”

The Canadian government is contributing $220 million to the facility. Its mandate includes delivering vaccines to “low- and middle-income countries.” Canada’s participation in the effort gives it the option of purchasing another 15 million doses of a vaccine.

“We cannot beat this virus in Canada unless we end it everywhere,” says Trudeau.

COVID-19 vaccine: U.S., China and Russia go it alone

But while Trudeau is pushing an international approach to find a vaccine, other countries are going it alone.

The COVAX facility is backed by some 172 countries, but the U.S. is not supporting the effort. Neither is China or Russia.

And while the race to find a COVID-19 vaccine has seen unprecedented cooperation between nations, some experts say it seems to be headed for the kind of scenario that plagued the search for a vaccine for AIDS in the 80s and 90s.

Back then, pharmaceutical companies and their research and development backers chased profits, making what treatments became available unaffordable for many, especially in the developing world.

In Canada, where large pharmaceuticals enjoy high-level access in Ottawa, who pays for a COVID-19 vaccine and whether it is subsidized are also emerging questions.

Canadians could be asked to pick up some of the cost.

“There’s a lot of money on the table,” says Thomas Tenkate, an associate professor at Ryerson University’s School of Occupational and Public Health.

He notes that pharmaceutical companies and their shareholders have historically placed a steep price on their research and development of new drugs.

Pandemic profiteering

While vaccines developed in the world have been distributed universally – polio comes to mind – the scenario with COVID-19 is shaping up to be much different. In all likelihood there will be multiple manufacturers distributing their own variations of the vaccine in different countries.

“With so many clinical trials on the boil you’ve got to think there will be a range available,” says Tenkate.

Tenkate says most researchers and countries will be looking to see what the U.S. does. “There’s a lot of political pressure in the U.S. to have something done [a vaccine] quickly.”

FDA approval usually opens the floodgates to approvals in other countries. But not necessarily in Canada, where Health Canada rules around the approval of new drugs are notoriously stringent.

At his press conference, Trudeau made a point of stressing that any vaccine approved for distribution in Canada will have to pass Health Canada standards. But that process can also be prone to politics.

Questions of transparency, for example, were recently raised about the government’s own Vaccine Task Force. The task force is made up of infectious disease experts and representatives of pharmaceutical companies. It’s advising the government on what research projects to explore.

Gary Kobinger, director of the Infectious Disease Research Centre at the Université Laval, quit the group last week citing potential conflicts among group members as a reason. “You need people to trust the vaccine,” Kobinger told the CBC.

The government responded by bringing in protocols that require potential conflicts of task force members to be made public.

Treatment not a cure

It usually takes anywhere from five to 10 years to develop a vaccine. But the big money is on a vaccine for COVID-19 by next spring or a little later. That’s a year and a half roughly since the onset of the disease.

Russia is already claiming to have developed a vaccine. The U.S. says it’s close. China has said a vaccine may be ready by November. The predictions are overly optimistic. Most of the larger clinical trials have just started in recent months.

There are some 126 clinical trials on the WHO’s radar. Some 26 involve human trials. Nine of those have reached phase three, but none will be completed until late 2022 at the earliest.

The largest human trial of 60,000 participants by Belgium-based Johnson & Johnson company Janssen Pharmaceutica won’t be completed until 2023, according to documents submitted to WHO.

The company says that it “anticipates the first batches of a COVID-19 vaccine to be available for emergency use authorization in early 2021, if proven to be safe and effective.”

Further monitoring of subjects after the trials are completed will be needed to make sure any side effects are manageable.

Tenkate worries that “corners may have to be cut because of the reduced timelines” to find a vaccine.

Whatever vaccine we end up with in the short term will be more akin to treatment than a cure.

Potential side effects

When politicians talk about a vaccine for COVID-19, it’s easy to jump to conclusions, but there is no magic pill. And there won’t be for some time, given that almost 20 years later there is no vaccine for SARS – COVID-19’s, genetic predecessor.

The danger with a COVID vaccine is that we will, in all likelihood, not know enough about the side effects.

Each country will have its own approval process. And while the rules around those “are pretty consistent around the world,” says Tenkate, there are differences. What is greenlighted for sale in Russia may not receive approval in other Western countries.

For Canada, it will come down to “understanding the risks,” Tenkate says, particularly with the possibility of multiple vaccines.

“Ultimately, for a lot of people, it’s going to come down to trust.”

@enzodimatteo


Let’s block ads! (Why?)



Source link

Continue Reading

Health

U.N. chief: time for national plans to help fund global COVID-19 vaccine effort – SaltWire Network

Published

 on


By Michelle Nichols and Stephanie Nebehay

NEW YORK/GENEVA (Reuters) – U.N. chief Antonio Guterres said on Wednesday it is time for countries to start using money from their national COVID-19 response to help fund a global vaccine plan as the World Bank warned that “broad, rapid and affordable access” to those doses will be at the core of a resilient global economic recovery.

The Access to COVID-19 Tools (ACT) Accelerator and its COVAX facility – led by the World Health Organization and GAVI vaccine alliance – has received $3 billion, but needs another $35 billion. It aims to deliver 2 billion vaccine doses by the end of 2021, 245 million treatments and 500 million tests.

At a high-level virtual U.N. event on the program, WHO chief Tedros Adhanom Ghebreyesus said the financing gap was less than 1% of what the world’s 20 largest economies (G20) had committed to domestic stimulus packages and “it’s roughly equivalent to what the world spends on cigarettes every two weeks.”

German Chancellor Angela Merkel pledged $100 million to GAVI to help poorer countries gain access to a vaccine and Johnson & Johnson Chief Executive Alex Gorsky committed 500 million vaccine doses for low-income countries with delivery starting in mid-2021.

“Having access to lifesaving COVID diagnostics, therapeutics or vaccines … shouldn’t depend on where you live, whether you’re rich or poor,” said Gorsky, adding that while Johnson & Johnson is “acting at an unprecedented scale and speed, but we are not for a minute cutting corners on safety.”

U.S. President Donald Trump has said that a vaccine against the virus might be ready before the Nov. 3 U.S. presidential election, raising questions about whether political pressure might result in the deployment of a vaccine before it is safe.

“We remain 100 percent committed to high ethical and scientific principles,” Gorsky said.

GAVI Chief Executive Seth Berkley said that so far 168 countries, including 76 self-financing states, have joined the COVAX global vaccines facility. Tedros said this represented 70% of the world’s population, adding: “The list is growing every day.”

China, Russia and the United States have not joined the facility, although WHO officials have said they are still holding talks with China about signing up. The United States has reached its own deals with vaccine developers.

‘LONG HAUL’

World Bank President David Malpass said the pandemic could push 150 million people into extreme poverty by 2021 and the “negative impact on human capital will be deep and may last decades.”

“Broad, rapid and affordable access to COVID vaccines will be at the core of a resilient global economic recovery that lifts everyone,” he said.

Guterres said that the ACT-Accelerator was the only safe and certain way to reopen the global economy quickly.

But he warned that the program needed an immediate injection of $15 billion to “avoid losing the window of opportunity” for advance purchase and production, to build stocks in parallel with licensing, boost research, and help countries prepare.

“We cannot allow a lag in access to further widen already vast inequalities,” Guterres said.

“But let’s be clear: We will not get there with donors simply allocating resources only from the Official Development Assistance budget,” he said. “It is time for countries to draw funding from their own response and recovery programs.”

U.N. Secretary-General Guterres called on all countries to step up significantly in the next three months.

Billionaire Bill Gates told the U.N. event that the Bill & Melinda Gates Foundation had signed an agreement with 16 pharmaceutical companies on Wednesday.

“In this agreement the companies commit to, among other things, scaling up manufacturing, at an unprecedented speed, and making sure that approved vaccines reach broad distribution as early as possible,” Gates said.

Britain’s Foreign Secretary Dominic Raab – a co-host of the meeting along with Guterres, the WHO and South Africa – urged other countries to join the global effort, saying the ACT-Accelerator is the best hope of bringing the pandemic under control.

Said Merkel: “We’re in for the long haul and we need more support.”

(Reporting by Michelle Nichols and Stephanie Nebehay; Editing by Chizu Nomiyama, Paul Simao and Jonathan Oatis)

Let’s block ads! (Why?)



Source link

Continue Reading

Health

U.N. chief: time to fund global COVID-19 vaccine effort with money from national plans – The Journal Pioneer

Published

 on


By Michelle Nichols and Stephanie Nebehay

NEW YORK/GENEVA (Reuters) – U.N. chief Antonio Guterres said on Wednesday it is time for countries to start using money from their national COVID-19 response to help fund a global vaccine plan as the World Bank warned that “broad, rapid and affordable access” to those doses will be at the core of a resilient global economic recovery.

The Access to COVID-19 Tools (ACT) Accelerator and its COVAX facility – led by the World Health Organization and GAVI vaccine alliance – has received $3 billion, but needs another $35 billion. It aims to deliver 2 billion vaccine doses by the end of 2021, 245 million treatments and 500 million tests.

At a high-level virtual U.N. event on the program, WHO chief Tedros Adhanom Ghebreyesus said the financing gap was less than 1% of what the world’s 20 largest economies (G20) had committed to domestic stimulus packages and “it’s roughly equivalent to what the world spends on cigarettes every two weeks.”

German Chancellor Angela Merkel pledged $100 million to GAVI to help poorer countries gain access to a vaccine and Johnson & Johnson Chief Executive Alex Gorsky committed 500 million vaccine doses for low-income countries with delivery starting in mid-2021.

“Having access to lifesaving COVID diagnostics, therapeutics or vaccines … shouldn’t depend on where you live, whether you’re rich or poor,” said Gorsky, adding that while Johnson & Johnson is “acting at an unprecedented scale and speed, but we are not for a minute cutting corners on safety.”

U.S. President Donald Trump has said that a vaccine against the virus might be ready before the Nov. 3 U.S. presidential election, raising questions about whether political pressure might result in the deployment of a vaccine before it is safe.

“We remain 100 percent committed to high ethical and scientific principles,” Gorsky said.

GAVI Chief Executive Seth Berkley said that so far 168 countries, including 76 self-financing states, have joined the COVAX global vaccines facility. Tedros said this represented 70% of the world’s population, adding: “The list is growing every day.”

China, Russia and the United States have not joined the facility, although WHO officials have said they are still holding talks with China about signing up. The United States has reached its own deals with vaccine developers.

‘LONG HAUL’

World Bank President David Malpass said the pandemic could push 150 million people into extreme poverty by 2021 and the “negative impact on human capital will be deep and may last decades.”

“Broad, rapid and affordable access to COVID vaccines will be at the core of a resilient global economic recovery that lifts everyone,” he said.

Guterres said that the ACT-Accelerator was the only safe and certain way to reopen the global economy quickly.

But he warned that the program needed an immediate injection of $15 billion to “avoid losing the window of opportunity” for advance purchase and production, to build stocks in parallel with licensing, boost research, and help countries prepare.

“We cannot allow a lag in access to further widen already vast inequalities,” Guterres said.

“But let’s be clear: We will not get there with donors simply allocating resources only from the Official Development Assistance budget,” he said. “It is time for countries to draw funding from their own response and recovery programs.”

U.N. Secretary-General Guterres called on all countries to step up significantly in the next three months.

Billionaire Bill Gates told the U.N. event that the Bill & Melinda Gates Foundation had signed an agreement with 16 pharmaceutical companies on Wednesday.

“In this agreement the companies commit to, among other things, scaling up manufacturing, at an unprecedented speed, and making sure that approved vaccines reach broad distribution as early as possible,” Gates said.

Britain’s Foreign Secretary Dominic Raab – a co-host of the meeting along with Guterres, the WHO and South Africa – urged other countries to join the global effort, saying the ACT-Accelerator is the best hope of bringing the pandemic under control.

Said Merkel: “We’re in for the long haul and we need more support.”

(Reporting by Michelle Nichols and Stephanie Nebehay; Editing by Chizu Nomiyama, Paul Simao and Jonathan Oatis)

Let’s block ads! (Why?)



Source link

Continue Reading

Trending